Respiratory Research Group, Hull York Medical School, Cottingham, UK.
Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Lung. 2021 Apr;199(2):121-129. doi: 10.1007/s00408-021-00437-7. Epub 2021 Apr 7.
This analysis assesses clinical characteristics of patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC) enrolled in a phase 2 study to better understand this patient population.
Patients with RCC/UCC lasting for ≥ 1 year and cough severity visual analog scale (VAS) score of > 40 mm at screening were eligible. Demographics, clinical characteristics, and medical history were collected at baseline. Cough-related measures included cough severity VAS, Cough Severity Diary (CSD), Leicester Cough Questionnaire (LCQ), and a structured cough-trigger questionnaire. Medication history included all medications 30 days before screening and chronic cough treatments within 1 year before screening. Data were summarized using descriptive statistics.
Patients (N = 253; female, 76%; mean age, 60 years) had severe (mean cough severity VAS, 57.5 mm) and long-lasting (median duration, 11 years) cough. The most burdensome self-reported aspects included psychological and social factors (LCQ) and cough frequency and intensity (CSD). Patient-reported triggers were consistent with cough hypersensitivity (e.g., 95% to 96% reported irritation or tickle in throat). Common reported comorbidities included gastroesophageal reflux disease (GERD; 56%), allergic rhinitis (47%), and asthma (30%); 12% of patients had been diagnosed with all 3 conditions. The most common prior medications included inhaled or oral steroids (21%), antihistamines (15%), and antacids (15%).
Patients with RCC/UCC had severe, long-lasting, and burdensome cough with clinical features of cough hypersensitivity. Many patients had been diagnosed with GERD, allergic rhinitis, and asthma but had a persistent cough despite treatment of these conditions.
ClinicalTrials.gov, NCT02612610; registered November 20, 2015.
本分析评估了参加 2 期研究的难治性慢性咳嗽（RCC）或不明原因慢性咳嗽（UCC）患者的临床特征，以便更好地了解这一患者人群。
符合条件的患者为 RCC/UCC 持续时间≥1 年且筛查时咳嗽严重程度视觉模拟量表（VAS）评分>40mm。在基线时收集了人口统计学、临床特征和病史。咳嗽相关措施包括咳嗽严重程度 VAS、咳嗽严重程度日记（CSD）、莱斯特咳嗽问卷（LCQ）和结构化咳嗽触发问卷。药物史包括筛查前 30 天的所有药物和筛查前 1 年内的慢性咳嗽治疗药物。使用描述性统计数据对数据进行总结。
患者（N=253；女性，76%；平均年龄，60 岁）有严重（平均咳嗽严重程度 VAS，57.5mm）和长期（中位数持续时间，11 年）咳嗽。自我报告的最具负担的方面包括心理和社会因素（LCQ）以及咳嗽频率和强度（CSD）。患者报告的触发因素与咳嗽高敏性一致（例如，95%至 96%的患者报告喉咙有刺激或刺痛感）。常见的报告合并症包括胃食管反流病（GERD；56%）、过敏性鼻炎（47%）和哮喘（30%）；12%的患者被诊断出同时患有这 3 种疾病。最常见的既往用药包括吸入或口服类固醇（21%）、抗组胺药（15%）和抗酸剂（15%）。
RCC/UCC 患者有严重、长期且负担沉重的咳嗽，具有咳嗽高敏性的临床特征。许多患者被诊断出 GERD、过敏性鼻炎和哮喘，但尽管治疗了这些疾病，仍持续咳嗽。
ClinicalTrials.gov，NCT02612610；注册日期：2015 年 11 月 20 日。
